Ayala Pharmaceuticals Inc (ADXS)

[trading_cyclist]

From Noelle this morning, for what it's worth.

Good morning,

Prior to the capital raise, we had enough cash to fund us into our fiscal 2019, which begins on November 1st of 2018.

The purpose of this capital raise is to bring in cash to fund our continued research and development initiatives to some of the important inflection points that we feel will create value for the shareholder. Some of the ways that we plan to use this funding are to invest in ongoing clinical research with axalimogene filolisbac, ADXS-PSA and ADXS-NEO, both in monotherapy and combination therapy, to expand our research initiatives with axalimogene filolisbac, ADXS-PSA and ADXS-NEO to additional indications and collaborations; and to progress our pre-clinical constructs, including the ADXS-HOT program, into clinical research in both monotherapy and combination therapy.

We continue to consider use of and utilize the various options available to us, both dilutive and non-dilutive, for funding the company. We have confidence in the science of Lm Technology and work to move our franchises forward every day.

I will pass your feedback along to the management team.

Best regards,

Noelle